Nifty
Sensex
:
:
16992.55
57720.37
47.50 (0.28%)
193.27 (0.34%)

Pharmaceuticals & Drugs - Veterinary

Rating :
38/99

BSE: 524669 | NSE: HESTERBIO

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 1,430.30
  • 47.93
  • 10
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 1,627.67
  • 0.59%
  • 5.21

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 53.73%
  • 3.04%
  • 32.96%
  • FII
  • DII
  • Others
  • 0.45%
  • 0.03%
  • 9.79%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 13.70
  • 11.57
  • 8.64

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 10.61
  • 4.89
  • 1.60

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 15.43
  • 8.71
  • 10.07

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 40.88
  • 47.88
  • 52.49

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 7.21
  • 7.48
  • 7.28

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 23.60
  • 24.41
  • 26.16

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Dec 22
Dec 21
Var%
Sep 22
Sep 21
Var%
Jun 22
Jun 21
Var%
Mar 22
Mar 21
Var%
Net Sales
74.94
55.69
34.57%
73.15
62.66
16.74%
50.70
60.19
-15.77%
56.47
64.17
-12.00%
Expenses
56.19
40.66
38.19%
60.41
45.10
33.95%
43.27
43.12
0.35%
46.14
44.40
3.92%
EBITDA
18.76
15.03
24.82%
12.74
17.56
-27.45%
7.43
17.07
-56.47%
10.33
19.78
-47.78%
EBIDTM
25.03%
26.99%
17.42%
28.02%
14.66%
28.36%
18.28%
30.82%
Other Income
4.39
2.78
57.91%
4.45
1.42
213.38%
3.12
2.35
32.77%
7.19
2.48
189.92%
Interest
3.89
0.96
305.21%
2.46
0.74
232.43%
1.60
0.86
86.05%
1.50
1.44
4.17%
Depreciation
5.24
5.17
1.35%
5.03
3.05
64.92%
5.06
3.23
56.66%
5.13
3.63
41.32%
PBT
14.02
11.68
20.03%
9.71
15.19
-36.08%
3.89
15.33
-74.62%
10.89
13.87
-21.49%
Tax
3.84
3.35
14.63%
3.67
4.06
-9.61%
1.90
4.31
-55.92%
2.30
3.77
-38.99%
PAT
10.18
8.33
22.21%
6.04
11.13
-45.73%
1.99
11.02
-81.94%
8.58
10.10
-15.05%
PATM
13.58%
14.96%
8.26%
17.76%
3.92%
18.31%
15.20%
15.74%
EPS
13.15
9.97
31.90%
8.16
12.49
-34.67%
4.66
14.68
-68.26%
9.08
11.39
-20.28%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Net Sales
255.26
235.01
214.33
183.27
178.07
135.94
123.11
100.89
90.64
69.05
65.10
Net Sales Growth
5.17%
9.65%
16.95%
2.92%
30.99%
10.42%
22.02%
11.31%
31.27%
6.07%
 
Cost Of Goods Sold
70.96
62.71
50.23
27.98
28.47
23.31
28.45
19.75
25.32
11.39
15.42
Gross Profit
184.30
172.29
164.11
155.29
149.60
112.63
94.65
81.14
65.32
57.65
49.68
GP Margin
72.20%
73.31%
76.57%
84.73%
84.01%
82.85%
76.88%
80.42%
72.07%
83.49%
76.31%
Total Expenditure
206.01
175.02
145.67
127.87
110.03
88.68
82.09
67.50
65.90
44.60
43.21
Power & Fuel Cost
-
10.28
7.57
8.13
7.83
6.37
5.59
5.81
4.77
4.40
3.30
% Of Sales
-
4.37%
3.53%
4.44%
4.40%
4.69%
4.54%
5.76%
5.26%
6.37%
5.07%
Employee Cost
-
45.33
38.92
40.65
28.93
23.24
18.32
15.44
12.32
9.84
9.06
% Of Sales
-
19.29%
18.16%
22.18%
16.25%
17.10%
14.88%
15.30%
13.59%
14.25%
13.92%
Manufacturing Exp.
-
13.36
11.60
11.98
11.34
9.45
7.06
7.85
5.25
5.28
4.15
% Of Sales
-
5.68%
5.41%
6.54%
6.37%
6.95%
5.73%
7.78%
5.79%
7.65%
6.37%
General & Admin Exp.
-
19.49
15.29
13.47
13.72
13.81
11.47
10.23
8.90
7.23
6.09
% Of Sales
-
8.29%
7.13%
7.35%
7.70%
10.16%
9.32%
10.14%
9.82%
10.47%
9.35%
Selling & Distn. Exp.
-
17.31
14.73
18.97
16.77
9.11
8.15
6.77
7.14
4.87
4.34
% Of Sales
-
7.37%
6.87%
10.35%
9.42%
6.70%
6.62%
6.71%
7.88%
7.05%
6.67%
Miscellaneous Exp.
-
6.53
7.34
6.69
2.98
3.40
3.05
1.64
2.20
1.58
4.34
% Of Sales
-
2.78%
3.42%
3.65%
1.67%
2.50%
2.48%
1.63%
2.43%
2.29%
1.29%
EBITDA
49.26
59.99
68.66
55.40
68.04
47.26
41.02
33.39
24.74
24.45
21.89
EBITDA Margin
19.30%
25.53%
32.03%
30.23%
38.21%
34.77%
33.32%
33.10%
27.29%
35.41%
33.63%
Other Income
19.15
13.74
4.68
6.37
7.21
2.55
0.42
0.88
0.34
0.79
0.20
Interest
9.45
4.06
6.60
7.37
6.63
4.04
3.50
3.72
4.83
6.46
3.26
Depreciation
20.46
16.58
13.31
13.07
11.76
9.66
7.00
5.75
5.92
5.41
4.43
PBT
38.51
53.08
53.42
41.33
56.86
36.12
30.93
24.81
14.33
13.37
14.41
Tax
11.71
14.02
15.40
10.32
16.16
13.05
8.15
5.63
4.82
4.20
5.34
Tax Rate
30.41%
26.41%
30.74%
24.97%
28.42%
36.13%
26.35%
22.69%
28.39%
31.41%
37.06%
PAT
26.79
38.90
34.43
29.17
41.56
25.62
23.55
19.19
12.47
9.45
9.26
PAT before Minority Interest
25.29
39.06
34.70
31.00
40.69
23.07
22.79
19.18
12.17
9.16
9.07
Minority Interest
-1.50
-0.16
-0.27
-1.83
0.87
2.55
0.76
0.01
0.30
0.29
0.19
PAT Margin
10.50%
16.55%
16.06%
15.92%
23.34%
18.85%
19.13%
19.02%
13.76%
13.69%
14.22%
PAT Growth
-33.98%
12.98%
18.03%
-29.81%
62.22%
8.79%
22.72%
53.89%
31.96%
2.05%
 
EPS
31.52
45.76
40.51
34.32
48.89
30.14
27.71
22.58
14.67
11.12
10.89

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Shareholder's Funds
259.99
228.31
201.07
177.46
140.63
121.95
101.71
84.92
75.01
67.30
Share Capital
8.51
8.51
8.51
8.51
8.51
8.51
8.51
8.51
8.51
8.51
Total Reserves
251.48
219.80
192.56
168.95
132.13
113.44
93.20
76.41
66.50
58.79
Non-Current Liabilities
197.87
113.72
96.64
69.64
44.41
48.32
41.28
37.66
20.46
16.31
Secured Loans
164.54
82.84
76.48
58.35
36.54
44.62
33.09
30.89
14.76
13.71
Unsecured Loans
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.90
0.76
0.00
Long Term Provisions
1.27
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Current Liabilities
96.90
61.37
83.46
48.66
54.63
38.01
38.20
35.01
45.47
38.89
Trade Payables
18.02
28.09
20.02
8.75
7.90
7.47
5.84
4.63
4.52
5.71
Other Current Liabilities
42.81
22.52
30.44
17.15
20.26
11.04
9.30
6.35
7.41
8.84
Short Term Borrowings
34.84
3.28
32.54
22.50
25.41
18.32
21.04
20.08
29.74
16.08
Short Term Provisions
1.22
7.48
0.46
0.26
1.07
1.18
2.02
3.95
3.80
8.27
Total Liabilities
562.17
411.05
386.59
299.46
244.04
212.88
185.84
160.46
142.22
123.70
Net Block
237.17
132.76
142.54
144.82
110.22
102.62
64.63
59.60
53.82
37.73
Gross Block
348.16
228.12
226.04
215.94
170.22
152.95
108.25
97.57
86.69
65.25
Accumulated Depreciation
110.99
95.36
83.50
70.98
60.00
50.33
43.62
37.97
32.87
27.52
Non Current Assets
367.40
249.54
227.29
157.80
145.59
132.91
111.63
100.45
85.12
73.90
Capital Work in Progress
81.91
109.17
74.15
7.05
31.81
21.29
36.46
32.60
20.55
28.89
Non Current Investment
21.24
0.00
0.00
0.00
0.00
0.00
0.07
0.28
0.28
0.28
Long Term Loans & Adv.
24.22
4.82
6.74
4.34
3.48
8.52
10.47
7.97
10.47
7.00
Other Non Current Assets
2.86
2.80
3.87
1.58
0.08
0.47
0.00
0.00
0.00
0.00
Current Assets
194.76
161.50
159.31
141.66
98.45
79.97
74.20
60.00
57.10
49.80
Current Investments
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Inventories
75.38
62.22
63.97
50.79
39.76
33.41
33.62
29.11
35.59
31.10
Sundry Debtors
55.28
49.21
58.44
32.87
32.29
26.53
26.24
17.76
14.06
15.04
Cash & Bank
25.20
21.27
23.53
41.05
13.39
11.48
5.28
6.58
4.85
2.63
Other Current Assets
38.90
2.56
5.18
5.63
13.01
8.54
9.05
6.55
2.60
1.03
Short Term Loans & Adv.
33.70
26.24
8.19
11.32
8.95
5.06
2.49
6.55
2.60
1.03
Net Current Assets
97.87
100.14
75.84
92.99
43.82
41.95
36.00
25.00
11.63
10.91
Total Assets
562.16
411.04
386.60
299.46
244.04
212.88
185.83
160.45
142.22
123.70

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Cash From Operating Activity
8.81
58.05
36.77
46.71
38.02
34.80
18.85
19.76
9.39
11.54
PBT
53.50
50.10
41.33
56.86
36.12
30.93
24.81
18.20
13.37
14.41
Adjustment
11.10
20.34
20.13
17.92
13.63
10.86
9.38
7.34
11.91
7.67
Changes in Working Capital
-38.68
1.54
-13.75
-12.26
-2.31
0.11
-9.37
-0.33
-6.02
-5.04
Cash after chg. in Working capital
25.92
71.99
47.71
62.52
47.44
41.90
24.82
25.21
19.25
17.04
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-17.11
-13.94
-10.94
-15.81
-9.41
-7.06
-5.97
-5.45
-9.86
-5.50
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
-0.04
0.00
0.00
0.00
0.00
Cash From Investing Activity
-116.59
-38.37
-74.47
-21.73
-25.83
-30.19
-13.30
-21.21
-14.59
-22.55
Net Fixed Assets
-84.72
-0.88
-5.09
-11.03
-20.52
-15.30
-6.87
-12.04
-10.39
-20.32
Net Investments
-20.81
-3.21
-12.45
-13.74
-5.88
0.07
0.21
-5.25
-0.85
-0.28
Others
-11.06
-34.28
-56.93
3.04
0.57
-14.96
-6.64
-3.92
-3.35
-1.95
Cash from Financing Activity
111.61
-18.22
18.74
2.65
-11.08
1.83
-6.68
6.76
7.38
9.90
Net Cash Inflow / Outflow
3.83
1.46
-18.96
27.63
1.12
6.45
-1.14
5.31
2.19
-1.12
Opening Cash & Equivalents
21.27
23.53
40.65
12.33
11.18
4.73
6.12
0.82
2.29
3.41
Closing Cash & Equivalent
24.75
21.27
23.53
40.65
12.33
11.18
4.99
6.12
4.48
2.29

Financial Ratios

Consolidated /

Standalone
Description
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Book Value (Rs.)
305.61
268.38
236.36
208.61
165.32
143.35
119.56
96.86
88.18
79.11
ROA
8.03%
8.70%
9.04%
14.97%
10.10%
11.43%
11.08%
8.06%
6.89%
8.28%
ROE
16.00%
16.16%
16.38%
25.59%
17.57%
20.38%
20.56%
15.46%
12.88%
14.28%
ROCE
14.02%
17.33%
16.53%
26.64%
20.20%
19.75%
18.98%
16.53%
17.78%
20.10%
Fixed Asset Turnover
0.82
0.95
0.83
0.92
0.84
0.96
1.00
1.01
0.93
1.04
Receivable days
81.15
91.49
90.92
66.77
78.70
76.80
77.96
63.83
75.19
80.59
Inventory Days
106.86
107.25
114.27
92.80
97.89
97.55
111.14
127.14
172.29
160.79
Payable days
134.17
174.82
42.10
27.25
33.70
33.48
29.56
28.17
45.39
41.89
Cash Conversion Cycle
53.84
23.92
163.09
132.33
142.89
140.87
159.54
162.80
202.09
199.49
Total Debt/Equity
0.86
0.46
0.60
0.51
0.49
0.54
0.58
0.71
0.64
0.48
Interest Cover
14.06
8.59
6.61
9.57
9.95
9.84
7.67
4.52
3.07
5.41

News Update:


  • Hester Biosciences - Quarterly Results
    31st Jan 2023, 12:39 PM

    Read More
  • Hester Biosciences acquires technology from ICAR-NIHSAD to develop H9N2 strain vaccine for poultry
    28th Dec 2022, 14:28 PM

    The agreement has signed for development and commercialization of the Low Pathogenic Avian Influenza (H9N2 strain) Inactivated Vaccine for poultry

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.